Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.
Acute Myeloid Leukaemia
COMBINATION_PRODUCT: S 64315 (also referred as MIK665) and venetoclax
Incidence of Dose Limiting Toxicity (DLTs), At the end of cycle 1 (each cycle is 21 or 28 days).|Incidence and severity of AEs, Through study completion, an average of 6 months.|Incidence and severity of SAEs, Through study completion, an average of 6 months.|Number of participants with dose interruptions "will be measured and reported in the Outcome Measure results data table., Through study completion, an average of 6 months.|Number of participants with dose reductions "will be measured and reported in the Outcome Measure results data table., Through study completion, an average of 6 months.|Dose intensity, Through study completion, an average of 6 months.
Anti-leukemic activity, Using blood, bone marrow aspirate and medullary biopsy if available according to ELN 2017 criteria, Through study completion, an average of 6 months.|Pharmacokinetic profile of S64315 administered in combination with Venetoclax in plasma: Area Under the Curve (AUC), From Day 1 of cycle 1 to the end of cycle 2 (each cycle is 21 or 28 days).|Pharmacokinetic profile of S64315 administered in combination with Venetoclax in plasma: Concentration at the end of infusion (Cinf), From Day 1 of cycle 1 to the end of cycle 2 (each cycle is 21 or 28 days).|Pharmacokinetic profile of S64315 administered in combination with Venetoclax in plasma: terminal half-life (tÂ½z), From Day 1 of cycle 1 to the end of cycle 2 (each cycle is 21 or 28 days).
The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.